Endothelial dysfunction in the pulmonary vascular bed

American Journal of the Medical Sciences

Volumn 320, Issue 4, 2000, Pages 223-232

  Chen, Y F ^a   Oparil, S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Endothelin; Endothelium derived hyperpolarizing factor; Nitric oxide; Prostacyclin; Pulmonary endothelial dysfunction

Indexed keywords

ENDOTHELIN 1; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; NITRIC OXIDE; PROSTACYCLIN;

BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; CARDIOPULMONARY BYPASS; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; LUNG ENDOTHELIUM; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; REVIEW; VASOCONSTRICTION;

EID: 0033791923     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200010000-00001     Document Type: Review

References (97)

1. Endothelium - The axis of vascular health and disease
2. The role of endothelium in cardiovascular homeostasis and disease
3. Nitric oxide generating vasodilators and 8-bromo-cGMP inhibit mitogenesis and proliferation of cultured rat smooth muscle cells
4. Endothelin 1: Mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells
5. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
6. Molecular biology of endothelins
7. Endothelin as a regulator of cardiovascular function in health and disease
8. Growth regulatory properties of endothelins
9. Endothelin, vascular hypertrophy, and hypertension
10. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling
11. Endothelin-1 and the regulation of vascular tone
12. Cloning and expression of a cDNA encoding an endothelin receptor
13. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
14. Endothelin receptor subtype: Distribution and function in the lung
15. A non-radioactive method for localization of endothelin receptor mRNA in situ
16. Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle
17. Endothelin B receptor agonists produce pulmonary vasodilation in the intact newborn lamb with pulmonary hypertension
18. Autoradiographic localization of endothelin-1 binding sites in the cardiovascular and respiratory systems
19. Distribution of endothelin-like immunoreactivity and mRNA in the developing and adult human lung
20. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat
21. Increased endothelin receptor gene expression in hypoxic rat lung
22. Pulmonary vascular response to endothelin in rats
23. Differences in vascular effects and removal of endothelin-1 in human lung, brain and skeletal muscle
24. Endothelin-1 induced potentiation of human airway smooth muscle proliferation: An ET-A receptor-mediated phenomenon
25. Endothelial dysfunction in pulmonary vascular disorders
26. Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat
27. Chronic hypoxia increases the number of endothelin-1 and endothelin-A receptor-positive vascular and alveolar cells in rat lung
28. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
29. Endothelin-A receptor antagonist, BQ123, prevents chronic hypoxia-induced pulmonary vascular remodeling in the rat
30. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats
31. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET-A receptor antagonist
32. Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats
33. Endothelin-A receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension
34. Endothelin-1 is elevated in monocrotaline pulmonary hypertension
35. Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow
36. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
37. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
38. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
39. Endothelium-derived relaxing and contracting factors
40. Nitric oxide: Physiology, pathophysiology, and pharmacology
41. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association
42. Effects of chronic hypoxia and altered hemodynamic on endothelial nitric oxide synthase expression in the adult rat lung
43. Cellular mechanisms of cyclic nucleotide-induced vasorelaxation
44. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium
45. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension
46. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation
47. Nitric oxide in the developing lung
48. Endothelium-dependent relaxation and cyclic GMP accumulation in rabbit pulmonary artery are selectively impaired by moderate hypoxia
49. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia
50. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung
51. Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat
52. Chronic hypoxia decreases nitric oxide production and endothelial nitric oxide synthase in newborn pig lungs
53. Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia
54. Hypoxia reduces atrial natriuretic peptide-clearance receptor gene expression in ANP knockout mice
55. Effect of inhaled nitric oxide on pulmonary function in cystic fibrosis
56. Impairment of pulmonary-artery endothelium-dependent relaxation in chronic obstructive lung disease is not due to dysfunction of endothelial cell membrane receptors nor to L-arginine deficiency
57. Reduced expression of endothelial nitric oxide synthase in the lung of patient with pulmonary hypertension
58. Hypoxia inhibits expression of eNOS via transcriptional and post-transcriptional mechanisms
59. Augmentation of hypoxic pulmonary vasoconstriction in the perfused rat lung by in vitro antagonists of endothelium-dependent relaxation
60. EDRF inhibition augments pulmonary hypertension in intact newborn lambs
61. Distribution of NOS in normoxic vs. hypoxic rat lung: Upregulation of NOS by chronic hypoxia
62. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension
63. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension
64. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling
65. A novel catheterization technique for the in vivo measurement of pulmonary vascular responses in the rat
66. Effects of charybdotoxin on responses to nitrovasodilators and hypoxia in the rat lung
67. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats
68. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3
69. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hypertensive to mild hypoxia
70. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
71. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension
72. Prostacyclin and prostaglandin E1: Molecular mechanisms and therapeutic utility
73. 2+ homeostasis and formation of cGMP and prostacyclin
74. The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling
75. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system
76. Phospholipase C activation by prostacyclin receptor agonist in cerebral microvascular smooth muscle cells
77. Gene expression of prostacyclin receptor in the hypertrophied heart of spontaneously hypertensive rats
78. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
79. Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension
80. Angiotensin II prevents hypoxic pulmonary hypertension and vascular changes in rat
81. Epoprostenol therapy for primary pulmonary hypertension
82. Inhaled prostacyclin in the treatment of pulmonary hypertension
83. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group
84. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension
85. Reactive oxygen species: Role in the relaxation induced by bradykinin or arachidonic acid via EDHF in isolated porcine coronary arteries
86. Endothelium-derived hyperpolarizing factor: A new endogenous inhibitor from the vascular endothelium
87. Hyperpolarizing factors
88. Angiotensin converting enzyme inhibitors and vascular protection in hypertension
89. Cytochrome P450 2C is an EDHF synthase in coronary arteries
90. Endothelium-derived hyperpolarizing factor(s): Species and tissue heterogeneity
91. Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation
92. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors
93. NO/PGI2-independent vasorelaxation and the cytochrome P450 pathway in rabbit carotid artery
94. + channels
95. + channels by endothelium-derived relaxing factors
96. Endothelium-derived relaxing, contracting and hyperpolarizing factors of mesenteric arteries of hypertensive and normotensive rats
97. Mechanisms of hypoxic pulmonary vasoconstriction: Can anyone be right?